The FDA on May 14, 2020, expanded the indication of POMALYST® to include treating adult patients with AIDS-related Kaposi Sarcoma, after failure of highly active antiretroviral therapy, and Kaposi Sarcoma in adult patients who are HIV-negative. POMALYST® is a product of Celgene Corporation.
Bottom Ad
Advertisement
Subscribe
